AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$INM

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $118K of INM (indirect holdings)

ADAR1 Capital Management, LLC purchased 91,101 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.30 ($1.29–$1.30, $0.12M total) across 3 trades over 2026-09-14 to 2026-09-16. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Sep 16, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INM
Neutral
high confidence
Mentioned
$INM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INMNeutralLow
01

Why it matters

The transaction adds modestly to insider ownership without immediate market impact.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical milestones for InMed could make this purchase more meaningful.

Relevance 5/10Novelty 5/10Timing: filed Sep 16, 2026

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$INMNeutralHigh confidence
Context

ADAR1 Capital Management bought 91,101 shares of InMed Pharmaceuticals at $1.30, raising its stake to 892,101 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The purchase size (~$118k) is small relative to market cap and typical trading volume.

Market effects

Sector

None; insider purchase does not signal sector-wide changes.

Regional

None; limited to the company.

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle confidence signal, but size is too small to act on.

Key entities

  • Company
    InMed Pharmaceuticals Inc.

    Biopharmaceutical company listed on NASDAQ.

  • Investor
    ADAR1 Capital Management, LLC

    Investment manager acting as 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INM insider trading history →

Related articles

SEP 9
$INMMed

InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

finanznachrichten.de2 min
JUL 22
$INMMed

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - InMed Pharmaceutica

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

benzinga.com4 min
JUL 6
$INMMed

InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

InMed Pharmaceuticals (NASDAQ: INM) said it amended a previously announced all-stock merger agreement with privately held Mentari Therapeutics and its merger subsidiaries. InMed filed a preliminary Form S-4 with the SEC for the deal. The boards approved; closing is expected in Q4 2026, pending shareholder approvals and S-4 effectiveness.

finanznachrichten.de3 min
JUN 4
$INMMedAI 8/10

InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals (NASDAQ: INM) said Nasdaq notified it on June 3, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid stayed at or above $1.00 for 10 straight business days (May 19–June 2). Nasdaq had flagged a failure to meet the $1.00 minimum for 30 days ending March 27. Nasdaq said the matter is closed.

finanznachrichten.de4 min